July 31st 2025
Taletrectinib was added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology as a preferred option for the first-line and subsequent treatment of advanced ROS1-positive non–small cell lung cancer (NSCLC).
Record High Pediatric Parainfluenza Virus Incidence in Finland
March 25th 2022Monthly parainfluenza virus incidence rates were nearly 6 times higher in September 2021 vs the second highest reported monthly incidence rates among children 4 years and younger in Finland in the last decade, following lifting of COVID-19–related restrictions.
Read More
Care for Migraine Insufficient in Germany, Online Survey Finds
March 25th 2022An online survey of migraineurs in Germany aimed to evaluate their most pressing unmet needs, with data collected on socioeconomic background, medical care experience, acute medication use, and migraine prophylaxis use and experience.
Read More
Meta-Analysis Finds Dupilumab Most Effective Biologic for CRS With Nasal Polyps
March 25th 2022A comparison of type 2 biologics indicated for the treatment of chronic rhinosinusitis with nasal polyps identified dupilumab as the most effective drug in decreasing nasal polyp score and nasal congestion severity, whereas benralizumab was least effective.
Read More
There is evidence that people with HIV may have increased risk of cardiovascular disease and researchers are still trying to understand why, said Jorge Plutzky, MD, director of the Vascular Disease Prevention Program and director of Preventive Cardiology at Brigham and Women’s Hospital and associate professor of medicine at Harvard Medical School.
Watch
Infliximab Biosimilar Maintains Outcomes, Remission Status After Switch From Originator
March 24th 2022Patients switched from the originator product maintained their clinical outcomes and remissions status while biologic-naïve patients recorded positive responses and remission outcomes after initiating infliximab-dyyb.
Read More
House Dust Mite Sublingual Immunotherapy Shows Promise in Atopic Dermatitis
March 23rd 2022Sublingual immunotherapy with Dermatophagoides pteronyssinus extract was associated with significant improvements in disease severity among patients with atopic dermatitis sensitized to the house dust mite.
Read More
Neutral Findings Predominate German Study of CGM Use
March 22nd 2022This new study from Germany evaluated the use of and satisfaction with continuous glucose monitors (CGMs) since health insurance companies in the country began reimbursement of the technology in 2016 for persons with insulin-dependent diabetes.
Read More
At the 2022 Community Oncology Conference, Elizabeth Spurlock, MA, PHR, director, Human Resources Business Partner, Texas Oncology, discussed the prevalence of burnout among physicians, staff, and administrators, and several strategies to reduce risk and support the health care workforce.
Watch
AAD 2022 to Address Diversity, Health Equity, and Emerging Therapeutics
March 21st 2022Emerging research on therapeutics and practical approaches to managing a myriad of dermatological conditions, as well as a growing focus on diversity, equity, and inclusion will be explored at the 2022 American Academy of Dermatology (AAD) Annual Meeting, which will take place March 25-29, in Boston, Massachusetts.
Read More
Dr Shoaib Ugradar Discusses Teprotumumab for Thyroid Eye Disease and Data Collected
March 21st 2022Teprotumumab has shown great efficacy in treating thyroid eye disease in both clinical trials and real-world settings, but more data are needed on adverse events, said Shoaib Ugradar, MD, UCLA Stein Eye Center Santa Monica.
Watch
Investigating How Care Fragmentation May Affect Primary Care Redesign in Medicare
March 20th 2022On this episode of Managed Care Cast, Lori Timmins, PhD, and Eugene Rich, MD, discuss the findings of their interim analysis of data from the first 3 years of the Comprehensive Primary Care Plus Initiative, a large-scale effort of primary care redesign meant to improve care fragmentation among Medicare fee-for-service beneficiaries.
Listen
Dupilumab Meaningfully Reduces Symptoms for Patients With EoE, Study Finds
March 19th 2022Compared with placebo, dupilumab treatment resulted in statistically significant and meaningful symptom improvements in adults and adolescents with eosinophilic esophagitis (EoE), according to abstracts presenting findings from the 3-part LIBERTY-EoE-TREET study.
Read More
Why Measures Matter—and How to Inspire Cancer Practices to Use Them
March 19th 2022Quality measures are the lifeblood of practice transformation, but learning which ones make a difference—and how to use them to drive change—is as much an art as a science, according to 3 oncology care leaders who discussed the topic Friday at the 2022 Community Oncology Conference, presented by the Community Oncology Alliance.
Read More
Study Findings Signal Some PE-Backed Dermatology Practices May Not Be Performing Well
March 18th 2022Public financial statements from 9 dermatology groups backed by private equity (PE) were analyzed by the researchers, who described a significant decrease in debt valuations of these groups both before and during the COVID-19 pandemic.
Read More
Study Finds C difficile Infection Manageable in Primary Care Settings With Specialist Guidance
March 17th 2022Cases of Clostridioides difficile (C diff) have increasingly been reported outside of typical settings, and a survey of general practitioners in France found that many cases can be managed without hospitalization.
Read More
Dr Michael Diaz on the Importance of Site of Care, PBM Reform
March 17th 2022Michael Diaz, MD, president and managing physician, Florida Cancer Specialists & Research Institute, speaks on takeaways from his discussions on site of care and pharmacy benefit managers (PBMs) at the 2022 Community Oncology Conference.
Watch
Dr Robert Sidbury Addresses Quality-of-Life Burden in Atopic Dermatitis
March 17th 2022Along with common symptoms of itch and pain, patients with atopic dermatitis experience significant work productivity and attention issues that affect overall quality of life, said Robert Sidbury, MD, MPH, chief, Division of Dermatology, Seattle Children's Hospital.
Watch